Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Julie M, Cherrington"'
Autor:
Kirsti Klemm, Sherwyn Schwartz, Julie M. Cherrington, Hans-Peter Guler, Jianke Li, Teresa Boyea, A. Marie O'Farrell
Publikováno v:
Current Medical Research and Opinion. 26:2003-2010
Dutogliptin is a novel, orally available, potent, and selective DPP4 inhibitor that improves glycemic control in type 2 diabetic patients. The objective of this study was to evaluate the potential pharmacokinetic and pharmacodynamic interactions, as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fb9ce6200958727f75ccd1f0adf9ae1
https://doi.org/10.1185/03007995.2010.491266
https://doi.org/10.1185/03007995.2010.491266
Autor:
Xinqiang Li, Jianke Li, Khalid Abou Farha, David Campbell, A. Marie O'Farrell, Julie M. Cherrington, Denise Hanway, Hans-Peter Guler, Andre van Vliet
Publikováno v:
Clinical Therapeutics. 29:1692-1705
Background: PHX1149 is a dipeptidyl peptidase-4 (DPP4) inhibitor that is currently in clinical development for the treatment of type 2 diabetes mellitus. PHX1149 is a small (molecular weight=241.16 Da), highly water-soluble (>2 g/mL), orally active m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d98fbf11f0443621581c8a032c0a6219
https://doi.org/10.1016/j.clinthera.2007.08.005
https://doi.org/10.1016/j.clinthera.2007.08.005
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(11)
The article by Mendel and colleagues, published in the January 1, 2003, issue of Clinical Cancer Research, described their novel preclinical approach to developing a thorough understanding of the exposure–activity relationship for sunitinib, a mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53dae8bc98399632d01d35ac4e7acd94
https://pubmed.ncbi.nlm.nih.gov/26034217
https://pubmed.ncbi.nlm.nih.gov/26034217
Autor:
A. Douglas Laird, Angela Barone, Dirk B. Mendel, Julie M. Cherrington, Guangmin Li, Katherine G. Moss, Olga Potapova, Michelle Nannini
Publikováno v:
Molecular Cancer Therapeutics. 5:1280-1289
Recent achievements in the development of multitargeted molecular inhibitors necessitate a better understanding of the contribution of activity against individual targets to their efficacy. SU11248, a small-molecule inhibitor targeting class III/V re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb7b56e1837fbb8cf98abe1e90e4d5e2
https://doi.org/10.1158/1535-7163.mct-03-0156
https://doi.org/10.1158/1535-7163.mct-03-0156
Autor:
Anne Marie O'Farrell, Kevin W.H. Yee, Julie M. Cherrington, Marcus M Schittenhelm, Troy Bainbridge, Laura McGreevey, Michael Heinrich, Ajia Town
Publikováno v:
Blood. 104:4202-4209
Fetal liver tyrosine kinase 3 internal tandem duplication (FLT3 ITD) mutations are the most common molecular abnormality associated with adult acute myeloid leukemia (AML). To exploit this molecular target, a number of potent and specific FLT3 kinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09691d2ff7e2aed89127826f3d19d6a3
https://doi.org/10.1182/blood-2003-10-3381
https://doi.org/10.1182/blood-2003-10-3381
Autor:
Julie M. Cherrington, Alyssa Morimoto, Beverly D. Smolich, Grant A. McArthur, Nguyen Tan, Kristina A. West, William C. Manning, Guy C. Toner
Publikováno v:
Oncogene. 23:1618-1626
Biomarkers that indicate biological activity and/or efficacy are a potentially useful tool in the development of molecularly targeted therapeutics. It is useful, though challenging, to identify biomarkers during preclinical development in order to im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c8bea5488cb9f30b7edb98f69b98c23
https://doi.org/10.1038/sj.onc.1207268
https://doi.org/10.1038/sj.onc.1207268
Autor:
Elias Anaissie, Stephan Faderl, Maureen Cooper, Alison L. Hannah, Maurizio Zangari, Nguyen Tan, Maher Albitar, Alison Stopeck, Guillermo Garcia-Manero, Hagop M. Kantarjian, Julie M. Cherrington, Francis J. Giles, Alyssa Morimoto, Jeffrey E. Lancet
Publikováno v:
Clinical Cancer Research. 10:88-95
Purpose: Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are of adverse prognostic significance in patients with multiple myeloma (MM). VEGF, a soluble circulating angiogenic molecule, acts via receptor tyrosin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a166324acc462a1aa318f396733d8ee2
https://doi.org/10.1158/1078-0432.ccr-0221-3
https://doi.org/10.1158/1078-0432.ccr-0221-3
Autor:
Lewis R. Silverman, Weiru Hong, Maher Albitar, Alison L. Hannah, Francis J. Giles, Helene A. Yuen, Jeffrey E. Lancet, Judith E. Karp, Srdan Verstovsek, Julie M. Cherrington, Maureen Cooper, Sharianne G. Louie, Hagop M. Kantarjian, Jorge E. Cortes, Susan O'Brien, Anne Marie O'Farrell, Alison Stopeck
Publikováno v:
Blood. 102:795-801
Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are adverse prognostic features in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDSs). VEGF is a soluble circulating angiogenic molecu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ce110f34d5b56909fef560691bf8f3c
https://doi.org/10.1182/blood-2002-10-3023
https://doi.org/10.1182/blood-2002-10-3023
Autor:
Lewis Silverman, Guillermo Garcia-Manero, Paul J. Shami, Judith E. Karp, Maurizio Zangari, Maher Albitar, Khuda D. Khan, Deborah A. Thomas, Hagop Kantarjian, Jeffrey E. Lancet, Alison T. Stopeck, Julie M. Cherrington, Maureen A. Cooper, Alison L. Hannah, Francis J. Giles
Publikováno v:
Cancer. 97:1920-1928
BACKGROUND Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are of adverse prognostic significance in patients with myeloproliferative disorders (MPD), including agnogenic myeloid metaplasia (AMM), chronic myelo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68edbaed758ad21423669d123e07c3fa
https://doi.org/10.1002/cncr.11315
https://doi.org/10.1002/cncr.11315
Autor:
Theresa J. Ngai, Weiru Hong, Jacqueline A Brassard, Paul K Keast, Anne Marie O'Farrell, Julie M. Cherrington, Lisa M. Olson, Tinya Abrams, Nancy Pryer, Lesley J. Murray, Kelly R. Long
Publikováno v:
Clinical & Experimental Metastasis. 20:757-766
The aim of the study was to investigate inhibitory effects of the receptor tyrosine kinase (RTK) inhibitor SU11248 against CSF-1R and osteoclast (OC) formation. We developed an in vivo model of breast cancer metastasis to evaluate efficacy of SU11248
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92ac586c26ab71c56f971c502b299488
https://doi.org/10.1023/b:clin.0000006873.65590.68
https://doi.org/10.1023/b:clin.0000006873.65590.68